1
|
Fisher JF, Mobashery S. β-Lactams against the Fortress of the Gram-Positive Staphylococcus aureus Bacterium. Chem Rev 2021; 121:3412-3463. [PMID: 33373523 PMCID: PMC8653850 DOI: 10.1021/acs.chemrev.0c01010] [Citation(s) in RCA: 41] [Impact Index Per Article: 13.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
Abstract
The biological diversity of the unicellular bacteria-whether assessed by shape, food, metabolism, or ecological niche-surely rivals (if not exceeds) that of the multicellular eukaryotes. The relationship between bacteria whose ecological niche is the eukaryote, and the eukaryote, is often symbiosis or stasis. Some bacteria, however, seek advantage in this relationship. One of the most successful-to the disadvantage of the eukaryote-is the small (less than 1 μm diameter) and nearly spherical Staphylococcus aureus bacterium. For decades, successful clinical control of its infection has been accomplished using β-lactam antibiotics such as the penicillins and the cephalosporins. Over these same decades S. aureus has perfected resistance mechanisms against these antibiotics, which are then countered by new generations of β-lactam structure. This review addresses the current breadth of biochemical and microbiological efforts to preserve the future of the β-lactam antibiotics through a better understanding of how S. aureus protects the enzyme targets of the β-lactams, the penicillin-binding proteins. The penicillin-binding proteins are essential enzyme catalysts for the biosynthesis of the cell wall, and understanding how this cell wall is integrated into the protective cell envelope of the bacterium may identify new antibacterials and new adjuvants that preserve the efficacy of the β-lactams.
Collapse
Affiliation(s)
- Jed F Fisher
- Department of Chemistry and Biochemistry, McCourtney Hall, University of Notre Dame, Notre Dame Indiana 46556, United States
| | - Shahriar Mobashery
- Department of Chemistry and Biochemistry, McCourtney Hall, University of Notre Dame, Notre Dame Indiana 46556, United States
| |
Collapse
|
2
|
Albayati ZAF, Penthala NR, Bommagani S, Post GR, Smeltzer MS, Crooks PA. Evaluation of bone and kidney toxicity of BT2-peg2, a potential carrier for the targeted delivery of antibiotics to bone. Toxicol Rep 2021; 8:359-364. [PMID: 33665133 PMCID: PMC7898066 DOI: 10.1016/j.toxrep.2021.02.002] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/07/2019] [Revised: 02/02/2021] [Accepted: 02/04/2021] [Indexed: 11/28/2022] Open
Abstract
Previous studies have demonstrated that the bone targeting agent BT2-peg2 (BT2-minipeg2, 9), when conjugated to vancomycin and delivered systemically by intravenous (IV) or intraperitoneal (IP) injection accumulates in bone to a greater degree than vancomycin alone, but that this accumulation is associated with severe nephrotoxicity. To determine whether this nephrotoxicity could be attributed to BT2-peg2 itself, we used a rat model to assess the distribution and toxicity of BT2-peg2 after IP injection of 11 mg/kg twice daily for 21 days. The results demonstrated that BT2-peg2 accumulates in bone but there was no evidence of nephrotoxicity or any histopathological abnormalities in the bone. This suggests the nephrotoxicity observed in previous studies is likely due to the altered pharmacokinetics of vancomycin when conjugated to BT2-peg2 rather than to BT2-peg2 itself. Thus, BT2-peg2 may be a safe carrier for the enhanced delivery of antibiotics other than vancomycin to the bone as a means of combating bone infection. However, the data also emphasizes the need to carefully examine the pharmacokinetic characteristics of any BT2-peg2-antibiotic conjugate utilized for treatment of bone infections.
Collapse
Affiliation(s)
- Zaineb A F Albayati
- Department of Pharmaceutical Sciences, College of Pharmacy, University of Arkansas for Medical Sciences, Little Rock, AR, 72205, United States
| | - Narsimha R Penthala
- Department of Pharmaceutical Sciences, College of Pharmacy, University of Arkansas for Medical Sciences, Little Rock, AR, 72205, United States
| | - Shobanbabu Bommagani
- Department of Pharmaceutical Sciences, College of Pharmacy, University of Arkansas for Medical Sciences, Little Rock, AR, 72205, United States
| | - Ginell R Post
- Department of Clinical Pathology, College of Medicine, University of Arkansas for Medical Sciences, Little Rock, AR, 72205, United States
| | - Mark S Smeltzer
- Department of Microbiology & Immunology, College of Medicine, University of Arkansas for Medical Sciences, Little Rock, AR, 72205, United States
| | - Peter A Crooks
- Department of Pharmaceutical Sciences, College of Pharmacy, University of Arkansas for Medical Sciences, Little Rock, AR, 72205, United States
| |
Collapse
|
3
|
Liu M, Feng M, Yang K, Cao Y, Zhang J, Xu J, Hernández SH, Wei X, Fan M. Transcriptomic and metabolomic analyses reveal antibacterial mechanism of astringent persimmon tannin against Methicillin-resistant Staphylococcus aureus isolated from pork. Food Chem 2020; 309:125692. [DOI: 10.1016/j.foodchem.2019.125692] [Citation(s) in RCA: 42] [Impact Index Per Article: 10.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/25/2019] [Revised: 10/08/2019] [Accepted: 10/09/2019] [Indexed: 12/20/2022]
|
4
|
Buommino E, Carotenuto A, Antignano I, Bellavita R, Casciaro B, Loffredo MR, Merlino F, Novellino E, Mangoni ML, Nocera FP, Brancaccio D, Punzi P, Roversi D, Ingenito R, Bianchi E, Grieco P. The Outcomes of Decorated Prolines in the Discovery of Antimicrobial Peptides from Temporin-L. ChemMedChem 2019; 14:1283-1290. [PMID: 31087626 DOI: 10.1002/cmdc.201900221] [Citation(s) in RCA: 19] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/08/2019] [Revised: 05/12/2019] [Indexed: 01/17/2023]
Abstract
Previously, we identified a potent antimicrobial analogue of temporin L (TL), [Pro3 ]TL, in which glutamine at position 3 was substituted with proline. In this study, a series of analogues in which position 3 is substituted with non-natural proline derivatives, was investigated for correlations between the conformational properties of the compounds and their antibacterial, cytotoxic, and hemolytic activities. Non-natural proline analogues with substituents at position 4 of the pyrrolidine ring were considered. Structure-activity relationship (SAR) studies of these analogues were performed by means of antimicrobial and cytotoxicity assays along with circular dichroism (CD) and NMR spectroscopic analyses for selected compounds. The most promising peptides were additionally evaluated for their activity against some representative veterinary microbial strains to compare with those from human strains. We identified novel analogues with interesting properties that make them attractive lead compounds.
Collapse
Affiliation(s)
- Elisabetta Buommino
- Department of Pharmacy, University of Naples "Federico II", Naples, 80131, Italy
| | - Alfonso Carotenuto
- Department of Pharmacy, University of Naples "Federico II", Naples, 80131, Italy
| | - Ignazio Antignano
- Department of Pharmacy, University of Naples "Federico II", Naples, 80131, Italy
| | - Rosa Bellavita
- Department of Pharmacy, University of Naples "Federico II", Naples, 80131, Italy
| | - Bruno Casciaro
- Department of Biochemical Sciences, Laboratory affiliated to Pasteur Institute Italia-Fondazione Cenci Bolognetti, Sapienza University of Rome, Rome, 00185, Italy.,Center for Life Nano Science, Istituto Italiano di Tecnologia, Rome, 00161, Italy
| | - Maria Rosa Loffredo
- Department of Biochemical Sciences, Laboratory affiliated to Pasteur Institute Italia-Fondazione Cenci Bolognetti, Sapienza University of Rome, Rome, 00185, Italy
| | - Francesco Merlino
- Department of Pharmacy, University of Naples "Federico II", Naples, 80131, Italy
| | - Ettore Novellino
- Department of Pharmacy, University of Naples "Federico II", Naples, 80131, Italy
| | - Maria Luisa Mangoni
- Department of Biochemical Sciences, Laboratory affiliated to Pasteur Institute Italia-Fondazione Cenci Bolognetti, Sapienza University of Rome, Rome, 00185, Italy
| | - Francesca Paola Nocera
- Department of Veterinary Medicine and Animal Production, University of Naples "Federico II", Naples, 80137, Italy
| | - Diego Brancaccio
- Department of Pharmacy, University of Naples "Federico II", Naples, 80131, Italy
| | - Pasqualina Punzi
- Peptide Chemistry Unit, IRBM S.p.A., via Pontina km 30 600, Pomezia, 00071, Italy
| | - Daniela Roversi
- Peptide Chemistry Unit, IRBM S.p.A., via Pontina km 30 600, Pomezia, 00071, Italy
| | - Raffaele Ingenito
- Peptide Chemistry Unit, IRBM S.p.A., via Pontina km 30 600, Pomezia, 00071, Italy
| | - Elisabetta Bianchi
- Peptide Chemistry Unit, IRBM S.p.A., via Pontina km 30 600, Pomezia, 00071, Italy
| | - Paolo Grieco
- Department of Pharmacy, University of Naples "Federico II", Naples, 80131, Italy.,Centro Interuniversitario di Ricerca sui Peptidi Bioattivi (CIRPEB), University of Naples "Federico II", Naples, 80134, Italy
| |
Collapse
|
5
|
Liu M, Yang K, Wang J, Zhang J, Qi Y, Wei X, Fan M. Young astringent persimmon tannin inhibits methicillin-resistant Staphylococcus aureus isolated from pork. Lebensm Wiss Technol 2019. [DOI: 10.1016/j.lwt.2018.10.047] [Citation(s) in RCA: 17] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/09/2023]
|
6
|
Afoullouss S, Calabro K, Genta-Jouve G, Gegunde S, Alfonso A, Nesbitt R, Morrow C, Alonso E, Botana LM, Allcock AL, Thomas OP. Treasures from the Deep: Characellides as Anti-Inflammatory Lipoglycotripeptides from the Sponge Characella pachastrelloides. Org Lett 2018; 21:246-251. [DOI: 10.1021/acs.orglett.8b03684] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/19/2022]
Affiliation(s)
- Sam Afoullouss
- Marine Biodiscovery, School of Chemistry and Ryan Institute, National University of Ireland Galway (NUI Galway), University Road, H91TK33 Galway, Ireland
- Zoology, School of Natural Sciences and Ryan Institute, National University of Ireland Galway (NUI Galway), University Road, H91TK33 Galway, Ireland
| | - Kevin Calabro
- Marine Biodiscovery, School of Chemistry and Ryan Institute, National University of Ireland Galway (NUI Galway), University Road, H91TK33 Galway, Ireland
| | - Grégory Genta-Jouve
- C-TAC, COMETE UMR 8638 CNRS, Université Paris Descartes, 4 avenue de l’observatoire, 75006 Paris, France
| | - Sandra Gegunde
- Departamento de Farmacología, Facultad de Veterinaria, Universidade de Santiago de Compostela, 27002 Lugo, Spain
| | - Amparo Alfonso
- Departamento de Farmacología, Facultad de Veterinaria, Universidade de Santiago de Compostela, 27002 Lugo, Spain
| | - Robert Nesbitt
- Marine Biodiscovery, School of Chemistry and Ryan Institute, National University of Ireland Galway (NUI Galway), University Road, H91TK33 Galway, Ireland
| | - Christine Morrow
- Zoology, School of Natural Sciences and Ryan Institute, National University of Ireland Galway (NUI Galway), University Road, H91TK33 Galway, Ireland
- Department of Natural Sciences, National Museums Northern Ireland, 153 Bangor Road, Cultra BT18 0EU, Northern Ireland
| | - Eva Alonso
- Departamento de Farmacología, Facultad de Veterinaria, Universidade de Santiago de Compostela, 27002 Lugo, Spain
| | - Luis M. Botana
- Departamento de Farmacología, Facultad de Veterinaria, Universidade de Santiago de Compostela, 27002 Lugo, Spain
| | - A. Louise Allcock
- Zoology, School of Natural Sciences and Ryan Institute, National University of Ireland Galway (NUI Galway), University Road, H91TK33 Galway, Ireland
| | - Olivier P. Thomas
- Marine Biodiscovery, School of Chemistry and Ryan Institute, National University of Ireland Galway (NUI Galway), University Road, H91TK33 Galway, Ireland
| |
Collapse
|
7
|
Merlino F, Carotenuto A, Casciaro B, Martora F, Loffredo MR, Di Grazia A, Yousif AM, Brancaccio D, Palomba L, Novellino E, Galdiero M, Iovene MR, Mangoni ML, Grieco P. Glycine-replaced derivatives of [Pro 3 ,DLeu 9 ]TL, a temporin L analogue: Evaluation of antimicrobial, cytotoxic and hemolytic activities. Eur J Med Chem 2017; 139:750-761. [DOI: 10.1016/j.ejmech.2017.08.040] [Citation(s) in RCA: 21] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/04/2017] [Revised: 08/03/2017] [Accepted: 08/19/2017] [Indexed: 12/23/2022]
|
8
|
Che JX, Shi JL, Lu Y, Liu YL. Validation of reference genes for normalization of gene expression by qRT-PCR in a resveratrol-producing entophytic fungus (Alternaria sp. MG1). AMB Express 2016; 6:106. [PMID: 27826948 PMCID: PMC5101243 DOI: 10.1186/s13568-016-0283-z] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/31/2016] [Accepted: 10/31/2016] [Indexed: 12/12/2022] Open
Abstract
Alternaria sp. MG1, an endophytic fungus isolated from Vitis vinifera, can independently produce resveratrol, indicating that this species contains the key genes for resveratrol biosynthesis. Identification of these key genes is essential to understand the resveratrol biosynthesis pathway in this strain, which is currently unknown in microorganisms. qRT-PCR is an efficient and widely used method to identify the key genes related to unknown pathways at the level of gene expression. Verification of stable reference genes in this strain is essential for qRT-PCR data normalization, although results have been reported for other Alternaria sp. strains. In this study, nine candidate reference genes including TUBA, EF1, EF2, UBC, UFD, RPS5, RPS24, ACTB and 18S were evaluated for expression stability in a diverse set of six samples representing different growth periods. We compared cell culture conditions and an optimized condition for resveratrol production. The comparison of the results was performed using four statistical softwares. A combination of TUBA and EF1 was found to be suitable for normalization of Alternaria sp. MG1 in different developmental stages, and 18S was found to be the least stable. The reference genes verified in this study will facilitate further research to explore gene expression and molecular mechanisms as well as the improvement of secondary metabolite yields in Alternaria sp. MG1. To our knowledge, this is the first validation of reference genes in Alternaria with the capability to produce resveratrol. Additionally, these results provide useful guidelines for the selection of reference genes in other Alternaria species.
Collapse
|
9
|
Yang Z, Liu Y, Ahn J, Qiao Z, Endres JL, Gautam N, Huang Y, Li J, Zheng J, Alnouti Y, Bayles KW, Li R. Novel fluorinated pyrrolomycins as potent anti-staphylococcal biofilm agents: Design, synthesis, pharmacokinetics and antibacterial activities. Eur J Med Chem 2016; 124:129-137. [PMID: 27565555 DOI: 10.1016/j.ejmech.2016.08.017] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/30/2016] [Revised: 07/20/2016] [Accepted: 08/09/2016] [Indexed: 12/15/2022]
Abstract
Staphylococcus aureus (SA) is a major cause of hospital- and community-associated bacterial infections in the U.S. and around the world. These infections have become increasingly difficult to treat due to the propensity to develop antibiotic resistance and form biofilm. To date, no antibiofilm agents are available for clinical use. To add to the repertoire of antibiotics for clinical use and to provide novel agents for combating both SA and biofilm infections, we previously reported marinopyrroles as potent anti-SA agents. In this study, we used fragment-based and bioisostere approaches to design and synthesize a series of novel fluorinated pyrrolomycins for the first time, performed analyses of their physicochemical and drug-like properties, and investigated structure activity relationships and pharmacokinetics. These promising fluorinated pyrrolomycins demonstrate potent antibacterial activity against SA with favorable drug-like properties and pharmacokinetic profiles. Importantly, these compounds kill staphylococcal biofilm-associated cells with a lack of mammalian cell cytotoxicity and no occurrence of bacterial resistance. Our novel fluorinated pyrrolomycin 4 has a clogP value of 4.1, an MIC of 73 ng/mL, MBC of 4 μg/mL, kill staphylococcal-associated biofilm at 8 μg/mL, bioavailability of 35%, and the elimination half-life of 6.04 h and 6.75 h by intravenous and oral administration, respectively. This is the first report of comprehensive drug discovery studies on pyrrolomycin-based antibiotics.
Collapse
Affiliation(s)
- Zunhua Yang
- UNMC Center for Drug Discovery and Department of Pharmaceutical Sciences, United States
| | - Yan Liu
- UNMC Center for Drug Discovery and Department of Pharmaceutical Sciences, United States
| | - Jongsam Ahn
- Department of Pathology and Microbiology, United States
| | - Zhen Qiao
- UNMC Center for Drug Discovery and Department of Pharmaceutical Sciences, United States
| | | | - Nagsen Gautam
- UNMC Center for Drug Discovery and Department of Pharmaceutical Sciences, United States
| | - Yunlong Huang
- Department of Pharmacology and Experimental Neuroscience, United States
| | - Jerry Li
- UNMC Center for Drug Discovery and Department of Pharmaceutical Sciences, United States
| | - Jialin Zheng
- Department of Pathology and Microbiology, United States; Department of Pharmacology and Experimental Neuroscience, United States
| | - Yazen Alnouti
- UNMC Center for Drug Discovery and Department of Pharmaceutical Sciences, United States
| | - Kenneth W Bayles
- Department of Pathology and Microbiology, United States; Center for Staphylococcal Research, United States
| | - Rongshi Li
- UNMC Center for Drug Discovery and Department of Pharmaceutical Sciences, United States; Center for Staphylococcal Research, United States; Fred and Pamela Buffett Cancer Center, University of Nebraska Medical Center, 986125 Nebraska Medical Center, Omaha, NE 68198, United States.
| |
Collapse
|
10
|
Abstract
After some years of stagnation there have been several new successful developments in the field of antibacterial agents. Most of these new developments have been in conventional antibacterial classes. New drugs among the beta-lactam agents are methicillin-resistant Staphylococcus aureus (MRSA) active cephalosporins (ceftaroline and ceftobiprole) and new combinations of beta-lactam with beta-lactamase inhibitors (ceftolozane/tazobactam, ceftazidime/avibactam, imipenem/relebactam and meropenem/RPX7009). New developments can also be observed among oxazolidinones (tedizolid, radezolid, cadazolid and MRX-I), macrolides/ketolides (modithromycin and solithromycin), aminoglycosides (plazomicin), quinolones (nemonoxacin, delafloxacin and avarofloxacin), tetracyclines (omadacycline and eravacycline) as well as among glycopeptides and lipopeptides (oritavancin, telavancin, dalbavancin and surotomycin). New agents in a very early developmental phase are FabI inhibitors, endolysines, peptidomimetics, lipid A inhibitors, methionyl-tRNA synthetase inhibitors and teixobactin.
Collapse
|
11
|
Jones JA, Virga KG, Gumina G, Hevener KE. Recent Advances in the Rational Design and Optimization of Antibacterial Agents. MEDCHEMCOMM 2016; 7:1694-1715. [PMID: 27642504 DOI: 10.1039/c6md00232c] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/05/2023]
Abstract
This review discusses next-generation antibacterial agents developed using rational, or targeted, drug design strategies. The focus of this review is on small-molecule compounds that have been designed to bypass developing bacterial resistance, improve the antibacterial spectrum of activity, and/or to optimize other properties, including physicochemical and pharmacokinetic properties. Agents are discussed that affect known antibacterial targets, such as the bacterial ribosome, nucleic acid binding proteins, and proteins involved in cell-wall biosynthesis; as well as some affecting novel bacterial targets which do not have currently marketed agents. The discussion of the agents focuses on the rational design strategies employed and the synthetic medicinal chemistry and structure-based design techniques utilized by the scientists involved in the discoveries, including such methods as ligand- and structure-based strategies, structure-activity relationship (SAR) expansion strategies, and novel synthetic organic chemistry methods. As such, the discussion is limited to small-molecule therapeutics that have confirmed macromolecular targets and encompasses only a fraction of all antibacterial agents recently approved or in late-stage clinical trials. The antibacterial agents selected have been recently approved for use on the U.S. or European markets or have shown promising results in phase 2 or phase 3 U.S. CLINICAL TRIALS
Collapse
Affiliation(s)
- Jesse A Jones
- Department of Biomedical and Pharmaceutical Sciences, Idaho State University, 1311 E. Central Drive, Meridian, ID 83642-7991 (USA)
| | - Kristopher G Virga
- Department of Pharmaceutical Sciences, Presbyterian College School of Pharmacy, 307 North Broad Street, Clinton, SC 29325 (USA)
| | - Giuseppe Gumina
- Department of Pharmaceutical Sciences, Presbyterian College School of Pharmacy, 307 North Broad Street, Clinton, SC 29325 (USA)
| | - Kirk E Hevener
- Department of Biomedical and Pharmaceutical Sciences, Idaho State University, 1311 E. Central Drive, Meridian, ID 83642-7991 (USA)
| |
Collapse
|
12
|
He M, Shao L, Liu Q, Li J, Lin H, Jing L, Li M, Chen D. Mechanism of synergy between SIPI-8294 and β-lactam antibiotics against methicillin-resistant Staphylococcus aureus. Lett Appl Microbiol 2016; 63:3-10. [PMID: 27173151 DOI: 10.1111/lam.12583] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/17/2016] [Revised: 04/18/2016] [Accepted: 05/10/2016] [Indexed: 12/13/2022]
Abstract
UNLABELLED SIPI-8294, as an erythromycin derivative, has only weak antibacterial effects on MRSA and MSSA. Interestingly, synergistic effect of SIPI-8294 with oxacillin was observed both in vitro and in vivo. Western blot and RT-PCR results demonstrate that mecA expressions were suppressed by SIPI-8294 in MRSA. Furthermore, the knock out of mecA in ATCC 43300 led to the loss of synergy of the combinations while mecA complemented strain showed almost the same synergistic capability compared to the wild type strain. However, the knock out of mecR1 and mecI in MRSA displayed no impact on the synergy of the combinations and the ability of SIPI-8294 to suppress mecA expression. In summary, our study has demonstrated that SIPI-8294 could dramatically reverse MRSA resistance to β-lactams both in vitro and in vivo owing to inhibiting mecA expression. However, mecR1 and mecI, as the pivotal regulatory genes of mecA, do not participate in SIPI-8294-mecA pathway. The research indicates that it may be a promising strategy for combating MRSA infections with the combinations of SIPI-8294 and β-lactam antibiotics. The research of the mechanism is important for structure modification and new drug development. SIGNIFICANCE AND IMPACT OF THE STUDY This study is the first report on the mechanism of synergy between SIPI-8294 and β-lactams against MRSA on the molecular level. In this study, SIPI-8294 showed strong synergistic effects on β-lactam antibiotics both in vitro and in vivo owing to inhibiting mecA expression. As pivotal regulatory genes of mecA, mecR1 and mecI do not participate in SIPI-8294-mecA pathway and are not involved in the synergism of SIPI-8294 and β-lactams. The research indicates that it may be a promising strategy for combating MRSA infections with the combinations of SIPI-8294 and β-lactams. The research is important for structure modification and new drug development.
Collapse
Affiliation(s)
- M He
- Shanghai Institute of Pharmaceutical Industry, China State Institute of Pharmaceutical Industry, Shanghai, China
| | - L Shao
- Shanghai Institute of Pharmaceutical Industry, China State Institute of Pharmaceutical Industry, Shanghai, China
| | - Q Liu
- Department of Laboratory Medicine, School of Medicine, Renji Hospital, Shanghai Jiaotong University, Shanghai, China
| | - J Li
- Shanghai Institute of Pharmaceutical Industry, China State Institute of Pharmaceutical Industry, Shanghai, China
| | - H Lin
- Shanghai Institute of Pharmaceutical Industry, China State Institute of Pharmaceutical Industry, Shanghai, China
| | - L Jing
- Shanghai Biotecan Pharmaceuticals Co., Ltd., Shanghai, China
| | - M Li
- Department of Laboratory Medicine, School of Medicine, Renji Hospital, Shanghai Jiaotong University, Shanghai, China
| | - D Chen
- Shanghai Institute of Pharmaceutical Industry, China State Institute of Pharmaceutical Industry, Shanghai, China
| |
Collapse
|
13
|
Monaco M, Pimentel de Araujo F, Cruciani M, Coccia EM, Pantosti A. Worldwide Epidemiology and Antibiotic Resistance of Staphylococcus aureus. Curr Top Microbiol Immunol 2016; 409:21-56. [PMID: 27025380 DOI: 10.1007/82_2016_3] [Citation(s) in RCA: 60] [Impact Index Per Article: 7.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
Abstract
Staphylococcus aureus is an important human pathogen, responsible for infections in the community and the healthcare setting. Although much of the attention is focused on the methicillin-resistant "variant" MRSA, the methicillin-susceptible counterpart (MSSA) remains a prime species in infections. The epidemiology of S. aureus, especially of MRSA, showed a rapid evolution in the last years. After representing a typical nosocomial multidrug-resistant pathogen, MRSA has recently emerged in the community and among farmed animals thanks to its ability to evolve and adapt to different settings. Global surveillance has shown that MRSA represents a problem in all continents and countries where studies have been carried out, determining an increase in mortality and the need to use last-resource expensive antibiotics. S. aureus can easily acquire resistance to antibiotics and MRSA is characteristically multidrug resistant. Resistance to vancomycin, the principal anti-MRSA antibiotic is rare, although isolates with decreased susceptibility are recovered in many areas. Resistance to the more recently introduced antibiotics, linezolid and daptomycin, has emerged; however, they remain substantially active against the large majority of MSSA and MRSA. Newer antistaphylococcal drugs have been developed, but since their clinical use has been very limited so far, little is known about the emergence of resistance. Molecular typing techniques have allowed to identify the major successful clones and lineages of MSSA and MRSA, including high-risk clones, and to trace their diffusion. In the face of a continuously evolving scenario, this review depicts the most common clones circulating in different geographical areas and in different settings at present. Since the evolution of S. aureus will continue, it is important to maintain the attention on the epidemiology of S. aureus in the future with a global view.
Collapse
Affiliation(s)
- Monica Monaco
- Department of Infectious, Parasitic and Immuno-mediated Diseases, Istituto Superiore di Sanità, Viale Regina Elena 299, 00161, Rome, Italy
| | - Fernanda Pimentel de Araujo
- Department of Infectious, Parasitic and Immuno-mediated Diseases, Istituto Superiore di Sanità, Viale Regina Elena 299, 00161, Rome, Italy
| | - Melania Cruciani
- Department of Infectious, Parasitic and Immuno-mediated Diseases, Istituto Superiore di Sanità, Viale Regina Elena 299, 00161, Rome, Italy
| | - Eliana M Coccia
- Department of Infectious, Parasitic and Immuno-mediated Diseases, Istituto Superiore di Sanità, Viale Regina Elena 299, 00161, Rome, Italy.
| | - Annalisa Pantosti
- Department of Infectious, Parasitic and Immuno-mediated Diseases, Istituto Superiore di Sanità, Viale Regina Elena 299, 00161, Rome, Italy.
| |
Collapse
|
14
|
Pasternak J. Antibiotics for Gram-negative infections. EINSTEIN-SAO PAULO 2015; 13:vii-viii. [PMID: 26466056 PMCID: PMC4943804 DOI: 10.1590/s1679-45082015ed3451] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022] Open
|